The Maker of Ozempic Is Trying to Block Compounded Versions of Its Drug

Compounded GLP‑1 Drugs: Role, Legality, and Safety

• Compounded drugs are described as custom formulations for allergies, unavailable doses, or alternative routes (e.g., liquids or flavored versions for animals).
• Concern: some compounders are effectively making unapproved “copycats” of patented drugs like semaglutide and tirzepatide, marketed as cheaper “generics” without FDA approval or full clinical testing.
• Veterinary and human anecdotes note that brand‑name formulations are the ones actually tested in trials; compounded versions may differ in efficacy and safety.
• FDA cannot “approve” compounded drugs; users debate trusting compounders versus sticking to branded injectors.
• Some compounding pharmacies allegedly crush branded pills (e.g., oral semaglutide) or import peptide powder from overseas; questions raised about purity, sterility, and patent infringement.
• Users debate whether current lawsuits and FDA warnings are primarily about safety or about protecting profits.

Access, Pricing, and Insurance Dynamics

• Branded Ozempic/Wegovy/Mounjaro can cost ~$1,000/month in the US; compounded versions are cited around ~$200–350/month.
• US prices are reported as far higher than in Canada/UK; some see this as deliberate price‑gouging, others as a byproduct of US policy and weak bargaining.
• Many insurers only cover GLP‑1s for diabetes, not weight loss, pushing non‑diabetics toward compounders or foreign sourcing.
• Commenters note employer‑driven plan design, churn between insurers, and unclear long‑term cost–benefit data as reasons for limited coverage.

Effectiveness, Side Effects, and Alternatives

• Multiple users report large weight losses and improved comorbidities (e.g., sleep apnea, exercise tolerance), saying GLP‑1s finally make constant hunger/cravings manageable.
• Others flag side effects and risks: testicular pain on finasteride, GI issues, possible nutrient deficits on very low intake, and unknown long‑term maintenance strategies.
• Debate on obesity: some argue “just diet and exercise” is unrealistic against powerful biological and environmental pressures; others emphasize discipline and nutrition strategies (e.g., keto, fiber).
• Exercise is praised for health and weight maintenance but described as an inefficient primary tool for large fat loss relative to calorie control.

Ethics, Patents, and Public Health

• Patents on semaglutide extend to ~2030; many see current enforcement and pricing as maximizing profit during monopoly years.
• Some argue these drugs have such profound potential for obesity and addiction that governments should force lower prices or broader licensing.
• Others accept patent rights but criticize using regulatory tools to suppress compounders while supply remains constrained.